

Exide Industries

Estimate changes	
TP change	
Rating change	

Bloomberg	EXID IN
Equity Shares (m)	850
M. Cap.(INRb)/(USDb)	278.8 / 3.1
52-Week Range (INR)	431 / 308
1, 6, 12 Rel. Per (%)	-9/-18/-22
12M Avg Val (INR M)	900

Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Net Sales	170.9	186.9	201.2
EBITDA	19.1	21.2	23.7
Adj. PAT	10.9	12.3	14.0
Adj. EPS (INR)	12.8	14.5	16.5
EPS Gr. (%)	0.9	13.4	13.6
BV/Sh. (INR)	180.6	192.9	206.6
Ratio			
RoE (%)	7.1	7.5	8.0
RoCE (%)	7.3	7.8	8.2
Payout (%)	15.6	15.5	16.7
Valuations			
P/E (x)	25.6	22.6	19.9
P/BV (x)	1.8	1.7	1.6
Div Yield (%)	0.6	0.7	0.8
FCF Yield (%)	4.1	4.1	4.3

Shareholding pattern (%)

As On	Dec-25	Sep-25	Dec-24
Promoter	46.0	46.0	46.0
DII	18.7	18.5	17.6
FII	10.9	10.9	11.7
Others	24.4	24.7	24.6

FII Includes depository receipts

CMP: INR328

TP: INR341(+4%)

Neutral

Weak 3Q due to headwinds in exports and telecom

Exports likely to pick up in coming quarters

- Exide's 3QFY26 PAT at INR2.6b came in below our estimate of INR2.8b due to lower-than-expected revenue growth even as margins were largely in line with our estimates. Despite the boost in auto sector demand after GST rate cuts, Exide's revenue grew just 5% YoY, mainly due to weak exports and a continued decline in the telecom segment.
- Given the underperformance in 3Q, we have lowered our earnings estimates by 5%/7% for FY26/FY27. The outlook for lead acid is positive for the auto segment and the industrial business (excl. telecom). However, we remain cautious about the long-term returns from the lithium-ion business. Besides, the stock at ~22.6x/19.9x FY27/28E EPS appears fairly valued. **Reiterate Neutral with an SoTP-based TP of INR341. We value the core (lead acid) business at 15x Dec'27E EPS (in line with Amara). We add INR59 per share value for the EV business (based on book) and INR52 per share for its stake in HDFC Life.**

PAT below estimate in 3Q due to export headwinds

- Exide's 3QFY26 revenues missed our estimates, growing 4.7% YoY to INR40.3b (vs. estimated INR44.3b). Overall, domestic business (ex-telecom) grew 10% YoY, led by the GST rate cut boost. However, exports dipped due to significant tariff-related headwinds.
- The auto OEM business grew more than 25% YoY, leading to higher market share across multiple segments. 2W/4W replacement business grew in double-digit on a YoY basis.
- Industrial infra business (ex-telecom) also grew in double digits as order inflow and order execution picked up in railways, traction and other sectors. Inverters and solar businesses are back on the growth path after a monsoon-led slowdown. Their outlook remains positive ahead of the peak season.
- EBITDA margin came in at 11.7%, largely in line with our estimate of 11.5%.
- Given a lower-than-expected revenue growth, EBITDA missed our estimates, growing 4.7% YoY to INR4.7b (estimate of INR5.1b).
- The company incurred a one-time exceptional expense of INR90.4m due to changes in the labor code.
- Adjusting for this expense, PAT came in at INR2.6b, up 7.9% YoY (below our estimate of INR2.8b).
- In the lithium-ion battery subsidiary, Exide has invested INR3.2b in 3Q and an additional INR500m in Jan'26. The total investment made to date stands at INR42.5b. Product validation is ongoing, with efforts to enter into collaboration with OEMs already underway.

Highlights from management call

- Exide has secured 100% share of business for key OEM programs, including Tata Sierra petrol (launched in Dec'25) and Kia Seltos facelift (4Q).
- Management indicated that export performance has largely bottomed out, with a recovery expected in FY27, supported by new channel partners, entry into newer geographies, and a favorable base effect.
- While the company did not increase prices in 3Q, it has taken a ~2% price hike in Jan to pass on the input cost pressure.
- Lithium-ion margins are expected to be superior to lead-acid, supported by indexed pricing, yield improvement, and local manufacturing advantages.
- Launched four new products in Feb: EL Ultra (premium automotive), Powerbox (mass segment), AGM batteries (premium PVs), and Solar Grid-Tie Inverters.
- Exide Energy has received cumulative equity infusion of ~INR42.5b, with the board approving an additional INR14b for FY27, ensuring adequate funding for capex, validation, and scale-up.

Valuation and view

- Given the underperformance in 3Q, we have lowered our earnings estimates by 5%/7% for FY26/FY27. The outlook for lead acid is positive for auto segment and industrial business (excl. telecom). However, we remain cautious about the long-term returns from the lithium-ion business. Besides, the stock at ~22.6x/19.9x FY27/28E EPS appears fairly valued. **Reiterate Neutral with an SOTP-based TP of INR341. We value the core (lead acid) business at 15x Dec'27E EPS (in line with Amara). We add INR59 per share value for the EV business (based on book) and INR52 per share for its stake in HDFC Life.**

Y/E March	S/A Quarterly Performance								(INR M)		
	FY25				FY26E				FY25	FY26E	2QE
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			
Net Sales	43,128	42,673	38,486	41,594	45,098	41,783	40,297	43,716	165,881	170,894	44,259
Growth YoY (%)	5.9	3.9	0.2	3.7	4.6	-2.1	4.7	5.1	3.5	3.0	15.0
RM cost (%)	69.3	68.5	68.0	68.8	69.2	70.1	68.4	69.0	68.7	69.2	70.0
Employee cost (%)	6.1	6.3	6.8	6.3	6.1	0.3	6.5	6.3	6.4	6.3	6.0
Other Exp(%)	13.1	13.9	13.5	13.7	12.6	14.0	13.4	13.3	13.6	13.3	12.5
EBITDA	4,943	4,836	4,486	4,667	5,482	3,960	4,696	4,971	18,931	19,095	5,090
EBITDA Margin (%)	11.5	11.3	11.7	11.2	12.2	9.5	11.7	11.4	11.4	11.2	11.5
Change (%)	14.4	0.1	2.0	-9.6	10.9	-18.1	4.7	6.5	1.2	3.3	13
Non-Operating Income	142	528	132	161	182	424	183	221	962	1,010	144
Interest	87	103	120	130	91	89	85	87	439	351	95
Depreciation	1,257	1,270	1,244	1,268	1,276	1,306	1,270	1,312	5,039	5,163	1,320
PBT after EO Exp	3,741	3,991	3,253	3,430	4,297	2,990	3,434	3,794	14,415	14,500	3,819
Effective Tax Rate (%)	25.3	25.4	24.7	25.8	25.4	25.7	25.0	25.8	25.3	25.5	25.5
Adj. PAT	2,796	2,978	2,450	2,546	3,205	2,221	2,644	2,814	10,769	10,870	2,845
Change (%)	15.6	3.8	2.0	-10.3	14.6	-25.4	7.9	10.5	2.3	0.9	16.1

Key performance indicators

Cost Break-up										
RM(%)	69.3	68.5	68.0	68.8	69.2	70.2	68.4	69.0	68.7	69.2
Employee cost (%)	6.1	6.3	6.8	6.3	6.1	6.4	6.5	6.3	6.4	6.3
Other Exp(%)	13.1	13.9	13.5	13.7	12.6	14.0	13.4	13.3	13.6	13.3
Gross Margin (%)	30.7	31.5	32.0	31.2	30.8	29.8	31.6	31.0	31.3	30.8
EBITDA Margin(%)	11.5	11.3	11.7	11.2	12.2	9.4	11.7	11.4	11.4	11.2
EBIT Margin(%)	8.5	8.4	8.4	8.2	9.7	7.3	9.0	8.9	8.4	8.7



Key takeaways from the management commentary

Key performance highlights

- Over 9MFY26, Exide's revenue growth remained muted at 2.3% YoY, while EBITDA and PAT declined 1% and 2.9% respectively, primarily due to persistent margin pressure and an adverse export mix.
- Domestic demand remained resilient across automotive replacement, OEMs, industrial infrastructure, and power, supported by improving rural sentiment, healthy automobile demand and replacement cycle normalization.
- Automotive replacement share stands at ~73-75% of auto mix.
- Exide has secured 100% share of business for key OEM programs, including the Tata Sierra petrol (launched Dec'25) and the domestic Kia Seltos facelift (4QFY26).
- Industrial (non-automotive) business, accounting for ~30% of revenue, delivered double-digit growth (excluding telecom), led by railways, power and data centers.
- Data center battery revenue stood at INR750m-INR1b per quarter, with strong RFQ activity and a multi-quarter tender conversion cycle. The industry capacity is expected to grow at ~20% CAGR.
- Inverter business, which makes up ~20% of annual revenue, remained stable in 3Q, with an uptick expected in 4Q driven by residential backup power demand and renewable integration. Solar batteries, which make up ~4-5% of revenue, were flat sequentially but are positioned for recovery.
- Export revenue declined 36.8% YoY in 3Q and 35.3% over 9M FY26, impacted by global macro uncertainty, regional conflicts, tariff uncertainty and pricing pressure from international competitors. International business now accounts for ~5-6% of total revenue. The company has entered new regions and expects an uptick in exports from 4Q onward.
- Management indicated that export performance has largely bottomed out, with a recovery expected in FY27, supported by new channel partners, entry into newer geographies, and a favorable base effect.
- The lead-acid business outlook remains positive, supported by strong replacement demand, railways-led industrial growth, and recovery in OEM production.
- Sequential improvement in gross margins was aided by operational efficiencies, cost-saving initiatives, and working-capital optimization, despite currency depreciation and elevated prices of antimony, silver (+50%), tin (+12%), sulphur (+40%), copper (+13%).
- While the company refrained from taking any price hikes in 3Q, it has now taken a ~2% price increase in Jan to pass on the input cost pressure.

Update on lithium-ion battery business

- Exide Energy has received cumulative equity infusion of ~INR42.5b, with the board approving an additional INR14b for FY27, ensuring adequate funding for capex, validation, and scale-up.
- The cylindrical cell line (primarily for two-wheelers) has completed electrode formation and is undergoing internal validation across safety, performance, and cycle life, with customer sampling expected shortly and production readiness targeted over the next 6-12 months.


- Prismatic cell lines (targeting 3W, e-rickshaws, stationary storage) have completed electrode manufacturing, with assembly, formation, and cycling systems under commissioning. Commercial production is expected in 3Q-4Q of FY27.
- Initial chemistry mix is expected to be ~50% LFP and ~50% NMC, aligned with OEM requirements. Margins are expected to be structurally superior to lead-acid, supported by indexed pricing, yield improvement, and local manufacturing advantages.

Other Highlights

- Working capital efficiency improved materially, with inventory days reduced from 110 to 95 days, and working capital as a percentage of revenue declining 440bp to 7.4%.
- The company remains debt-free, with all capex funded through internal accruals.
- Launched four new products in Feb - EL Ultra (premium automotive), Powerbox (mass segment), AGM batteries (premium PVs), and Solar Grid-Tie Inverters.

Exhibit 1: Trends in revenue and growth


EXIDE Market Trend (Q3 FY26) and Outlook (Q4 FY26)



Source: Company, MOFSL


Key exhibits

Exhibit 2: Trends in revenue and growth




Source: Company, MOFSL

Exhibit 3: Trend in gross margin




Source: Company, MOFSL

Exhibit 4: Trend in EBITDA margin




Source: Company, MOFSL

Exhibit 5: Trend in PAT and growth



Source: Company, MOFSL

Exhibit 6: Lead price has inched up recently



Source: Company, MOFSL

Valuation and view


- **EXID continues to enjoy a strong position in the LAB industry:** EXID remains a market leader across all key segments in the lead acid battery (LAB) industry, except telecom. In the auto OEM segment, EXID has a dominant presence in both 2Ws and 4Ws. Even in the replacement battery segment, it largely is a duopoly market, with EXID being the market leader. It also has a strong position in both the UPS and inverter segments. Apart from this, it is a dominant player in power and traction batteries. It has the largest distribution network in India, with 115k channel partners. Through digitization initiatives, it is now able to give on-the-spot warranty resolutions, which is one of the USPs for the company. With a recovery in LAB post the GST rate cuts in both OE and replacement segments, Exide will emerge as one of the major beneficiaries of the same
- **EV transition is the real risk for LAB in long run:** The transition to EVs in India and globally is emerging as a big risk for LAB players in the long run. The only saving grace for Indian players in the near term is that the EV transition is picking up pace in 2Ws and 3Ws only at present, and for PVs, it may take a bit longer. However, lithium-ion batteries are now increasingly finding applications in various industrial use cases, including in telecom, traction, UPS, etc. Transition to lithium-ion gradually in several segments remains a key risk for large LAB players like Exide.
- **Foray into lithium-ion will have its own challenges:** Given the significant imminent risk to its core business, EXID has forayed into the manufacturing of lithium-ion cells in partnership with S-Volt at a total investment of INR60b in two phases. Further, EXID recently announced that it has secured a non-binding partnership with Hyundai-Kia for localization of LFP cells for one of their global platforms to be produced in India. While EXID can fund this venture through its internal accruals without needing any major funding for this phase, we believe the company's foray into lithium-ion cell manufacturing is likely to see multiple challenges in the coming years, as: 1) most domestic PV OEMs either have their own lithium-ion manufacturing plans or have existing tie-ups, limiting EXID's potential addressable market in this space; 2) the current partnership with Hyundai is non-binding, and hence we need to wait to understand whether this eventually moves into a binding partnership; 3) EXID is setting up a greenfield in this segment without prior experience; we expect its facility to take at least a couple of years to stabilize operations as it goes through its testing and validation phase initially for interested OEMs; 4) EXID is not participating in PLI, which would limit its competitiveness relative to peers that qualify for the same; 5) given the lithium-ion cell manufacturing is a low-margin business globally, we expect this business to be return-dilutive for EXID in the long run, even if this venture is successful; 6) given the significant capital commitment required and doubts about the sustainability of this technology in the long run, we believe the outcome of this venture remains highly uncertain at this stage.
- **Valuation and view:** Given the underperformance in 3Q, we have lowered our earnings estimates by 5% / 7% for FY26E / FY27E. The outlook for lead acid is positive for auto segment as also Industrial business (ex telecom). However, we continue to remain cautious about the long-term returns from the lithium-ion business. Besides, the stock at ~22.6x/19.9x FY27/28E EPS appears fairly valued. **Reiterate Neutral with an SOTP-based TP of INR341. We value the core (lead acid) business at 15x Dec'27E EPS (in line with Amara). We add INR59 per share value for the EV business (based on book) and INR52 per share for its stake in HDFC Life.**

Exhibit 7: Our revised estimates

(INR m)	FY26E			FY27E		
	Rev	Old	Chg (%)	Rev	Old	Chg (%)
Net Sales	170,894	176,724	-3.3	186,937	193,182	-3.2
EBITDA Margin (%)	11.2	11.3	-20bp	11.4	11.9	-60bp
PAT	10,870	11,432	-4.9	12,327	13,263	-7.1
EPS (INR)	12.8	13.4	-4.9	14.5	15.6	-7.1

Source: MOFSL

Exhibit 8: Valuations – P/E and P/B trading bands



Story in charts

Exhibit 9: Trends in revenue and growth






Exhibit 10: Trends in EBITDA and EBITDA margin



Source: Company, MOFSL


Source: Company, MOFSL

Exhibit 11: PAT and PAT growth trends




Source: Company, MOFSL

Exhibit 12: Strong FCF driven by healthy CFO




Source: Company, MOFSL

Exhibit 13: Trend in return ratios



Source: Company, MOFSL

Exhibit 14: Dividend yield and dividend payout (%) trends



Source: Company, MOFSL

Financials and valuations

Income Statement									(INR M)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E	
Total Income	1,00,408	1,24,101	1,45,919	1,60,292	1,65,881	170,894	186,937	201,188	
Change (%)	1.9	23.6	17.6	9.8	3.5	3.0	9.4	7.6	
EBITDA	13,557	13,984	15,681	18,715	18,932	19,096	21,226	23,705	
EBITDA Margins (%)	13.5	11.3	10.7	11.7	11.4	11.2	11.4	11.8	
Change (%)	-0.7	3.1	12.1	19.3	1.2	0.9	11.2	11.7	
Depreciation	3,794	4,131	4,558	4,975	5,039	5,163	5,386	5,621	
EBIT	9,763	9,852	11,123	13,740	13,893	13,933	15,840	18,084	
Interest Charges	238	394	295	486	439	351	379	410	
Other Income	654	805	1,324	845	962	1,010	1,042	1,075	
EO Exp/(Inc)	-	(46,938)	-	-	-	-	-	-	
PBT	10,179	57,199	12,151	14,099	14,415	14,500	16,501	18,748	
Tax	2,596	10,356	3,115	3,569	3,646	3,698	4,175	4,743	
Effective Rate (%)	25.5	18.1	25.6	25.3	25.3	25.5	25.3	25.3	
Rep. PAT	7,583	46,843	9,036	10,530	10,769	10,803	12,327	14,005	
Change (%)	-8.1	517.8	-80.7	16.5	2.3	0.3	14.1	13.6	
Adj. PAT	7,583	8,404	9,036	10,530	10,769	10,870	12,327	14,005	
Change (%)	-10.0	10.8	7.5	16.5	2.3	0.9	13.4	13.6	
Balance Sheet									(INR M)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E	
Share Capital	850	850	850	850	850	850	850	850	
Reserves	68,085	1,05,131	1,11,248	1,30,522	1,43,573	152,676	163,090	174,758	
Net Worth	68,935	1,05,981	1,12,098	1,31,372	1,44,423	153,526	163,940	175,608	
Loans	0	0	2,708	3,856	3,752	3,752	3,752	3,752	
Deferred Tax Liability	771	-654	-1,160	-137	108	108	108	108	
Capital Employed	69,706	1,05,327	1,13,646	1,35,092	1,48,283	157,386	167,800	179,467	
Application of Funds									
Gross Fixed Assets	42,740	48,245	53,473	58,005	62,447	67,447	72,447	77,447	
Less: Depreciation	16,361	20,509	24,970	29,353	33,687	38,850	44,236	49,857	
Net Fixed Assets	26,379	27,736	28,503	28,652	28,759	28,596	28,210	27,589	
Capital WIP	2,008	3,124	1,009	2,017	1,375	1,375	1,375	1,375	
Investments	31,012	60,773	63,477	86,258	99,766	108,206	118,206	127,206	
Curr. Assets	36,889	41,352	46,362	51,600	58,291	55,261	59,445	65,740	
Inventory	23,462	24,647	29,891	32,493	38,274	35,115	38,412	41,340	
Sundry Debtors	8,874	11,945	12,745	12,650	15,772	14,982	16,389	17,638	
Cash & Bank Balance	825	1,536	681	2,174	1,113	1,886	1,059	1,250	
Other Current Assets	3,728	3,223	3,045	4,282	3,132	3,277	3,585	5,512	
Current Liab. & Prov.	26,582	27,657	25,705	33,435	39,908	36,052	39,436	42,442	
Sundry Creditors	16,483	16,268	15,360	23,199	28,431	21,069	23,047	24,804	
Other Liabilities	6,856	8,191	6,962	6,456	6,794	11,237	12,292	13,229	
Provisions	3,244	3,198	3,383	3,780	4,683	3,746	4,097	4,410	
Net Current Assets	10,307	13,695	20,657	18,165	18,383	19,209	20,009	23,298	
Application of Funds	69,705	1,05,327	1,13,646	1,35,092	1,48,283	157,386	167,800	179,468	

E: MOFSL Estimates

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Basic (INR)								
EPS	8.9	9.9	10.6	12.4	12.7	12.8	14.5	16.5
Cash EPS	13.4	14.7	16.0	18.2	18.6	18.9	20.8	23.1
Book Value per Share	81.1	124.7	131.9	154.6	169.9	180.6	192.9	206.6
DPS	2.0	3.2	2.0	2.0	2.0	2.0	2.3	2.8
Payout (Incl. Div. Tax) %	22.4	32.4	18.8	16.1	15.8	15.6	15.5	16.7
Valuation (x)								
P/E	36.8	33.2	30.8	26.5	25.9	25.6	22.6	19.9
Cash P/E	24.5	22.2	20.5	18.0	17.6	17.4	15.7	14.2
EV/EBITDA	18.2	15.5	13.9	10.4	9.6	9.0	7.7	6.5
EV/Sales	2.5	1.7	1.5	1.2	1.1	1.0	0.9	0.8
Price to Book Value	4.0	2.6	2.5	2.1	1.9	1.8	1.7	1.6
Dividend Yield (%)	0.6	1.0	0.6	0.6	0.6	0.6	0.7	0.8
Profitability Ratios (%)								
RoE	11.0	7.9	8.1	8.0	7.5	7.1	7.5	8.0
RoCE	11.8	10.0	8.4	8.7	7.8	7.3	7.8	8.2
RoIC	19.6	21.3	18.7	22.0	22.9	22.6	25.4	27.9
Turnover Ratios								
Debtors (Days)	32	35	32	29	35	32	32	32
Inventory (Days)	85	72	75	74	84	75	75	75
Creditors (Days)	60	48	38	53	63	45	45	45
Working Capital (Days)	58	60	68	50	56	62	62	62
Gross Fixed Asset Turnover (x)	2.3	2.6	2.7	2.8	2.7	2.5	2.6	2.6
Leverage Ratio								
Net Debt/Equity (x)	-0.1	-0.1	0.0	0.0	0.0	0.0	0.0	0.0

Cash Flow Statement

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	(INR M) FY28E
OP/(Loss) before Tax	10,179	57,199	12,151	14,099	14,415	13,932	15,839	18,083
Interest/Dividends Received	-362	-225	-233	-237	-212	1,010	1,042	1,075
Depreciation & Amortisation	3,794	4,131	4,558	4,975	5,039	5,163	5,386	5,621
Direct Taxes Paid	-2,721	-10,472	-3,212	-3,707	-3,726	-3,698	-4,175	-4,743
(Inc)/Dec in Working Capital	3,044	-3,479	-4,538	4,874	-2,637	-7	-1,626	-3,098
Other Items	200	-46,951	-242	-38	100	-90	0	0
CF from Oper. Activity	14,134	205	8,484	19,965	12,979	16,310	16,465	16,937
(Inc)/Dec in FA+CWIP	-3,384	-5,783	-3,493	-4,844	-4,245	-5,000	-5,000	-5,000
Free Cash Flow	10,750	-5,579	4,991	15,122	8,735	11,310	11,465	11,937
(Pur)/Sale of Invest.	-9,385	8,537	-5,385	-11,328	-7,558	-8,486	-10,000	-9,000
CF from Inv. Activity	-12,769	2,754	-8,878	-16,172	-11,803	-13,486	-15,000	-14,000
Interest Rec./(Paid)	-289	-549	-461	-601	-539	-351	-379	-410
Dividends Paid	-1,700	-1,698	0	-2,848	-1,596	-1,700	-1,913	-2,338
CF from Fin. Activity	-1,989	-2,247	-461	-2,301	-2,239	-2,051	-2,292	-2,747
Inc/(Dec) in Cash	-623	711	-855	1,493	-1,062	773	-826	190
Add: Beginning Balance	1,449	826	1,536	681	2,174	1,113	1,886	1,059
Closing Balance	826	1,536	681	2,174	1,113	1,885	1,059	1,250

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Rajani

Name: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN .. 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrivances@motilaloswal.com.